Drug-drug interactions: Clinical perspective

Drug-Drug Interactions

Volumn , Issue , 2001, Pages 565-584

  Greenblatt, David J ^a   Von Moltke, Lisa L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038680172     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (56)

1. Harvey AT and Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology 1996; 16: 273-285,345-355.
2. DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999; 19: 443-466.
3. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1997; 32 (Supp. 1): 1-21.
4. Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997; 17: 390-406.
5. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72: 835-847.
6. Sproule BA, Naranjo CA, Bremner KE and Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clinical Pharmacokinetics 1997; 33: 454-471.
7. Baker GB, Fang J, Sinha S and Coutts RT. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehavioral Rev 1998; 22: 325-333.
8. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444-469.
9. Greenblatt DJ, von Moltke LL, Harmatz JS and Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998; 59 (Supp. 15): 19-27.
10. Greenblatt DJ, von Moltke LL, Harmatz JS and Shader RI. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999; 19 (Suppl. 1): 23S-35S.
11. Venkatakrishnan K, von Moltke LL and Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
12. Periti P, Mazzei T, Mini E and Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106-131.
13. Gillum JG, Israel DS and Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-482.
14. Barry M, Gibbons S, Back D and Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209.
15. Barry M, Mulcahy F, Merry C, Gibbons S and Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HlV infection. Clin Pharmacokinet 1999; 36: 289-304.
16. Hsu A, Granneman GR and Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HlV agents. Clin Pharmacokinet 1998; 35: 275-291.
17. Tucker GT. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992; 30: 550-553.
18. Bertz RJ and Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.
19. Rodrigues AD and Wong SL. Application of human liver microsomes in metabolism- based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. Adv Pharmacol 1997; 43: 65-101.
20. Rodrigues AD. Use of in vitro human metabolism studies in drug development. Biochem Pharmacol 1994; 48: 2147-2156.
21. Lin JH and Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-390.
22. Thummel KE and Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430.
23. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39;1-7.
24. Clarke SE. In vitro assessment of human cytochrome P450. Xenobiotica 1998; 28: 1167-1202.
25. Smith G, Stubbins MJ, Harries LW and Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1998; 28: 1129-1165.
26. Smith DA, Abel SM, Hyland R and Jones BC. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 1998; 28: 1095-1128.
27. Glue P and Clement RP. Cytochrome P450 enzymes and drug metabolism-basic concepts and methods of assessment. Cell Mol Neurobiol 1999; 19: 309-323.
28. Crespi CL and Penman BW. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 1997; 43: 171-188.
29. von Moltke LL, Greenblatt OJ, Schmider J, Wright CE, Harmatz JS and Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacal 1998; 55: 113-122.
30. Fahey JM, Pritchard GA, von Moltke LL, Pratt JS, Grassi JM, Shader RI and Greenblatt OJ. The effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. J Pharmacol Exp Ther 1998; 285: 271-276.
31. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-412.
32. Waxman OJ and Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992; 281 : 577-592.
33. Park BK, Kitteringham NR, Piromohamed M and Tucker GT. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 1996; 41: 477-491.
34. Halpert JR. Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 1995; 35: 29-53.
35. Lin JH and Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacological Rev 1997; 49: 403-449.
36. Silverman R. Mechanism-based enzyme inactivators. Meth Enzymol 1992; 249: 241-282.
37. Greenblatt DJ and von Moltke LL. Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In: W Hori, ed. Drug-Drug Interactions: Analyzing In Vitro-In Vivo Correlations. Southboro, MA: International Business Communications, 1997, pp 2.2.1-2.2.28.
38. von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS and Shader RI. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharmaceut Sci 1998; 87: 1184-1189.
39. Li AP and Jurima-Romet M. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol 1997; 13: 365-374.
40. Maurel P. The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Advanced Drug Deliv Rev 1996; 22: 105-132.
41. George J, Goodwin B, Liddle C, Tapner M and Farrell GC. Time-dependent expression of cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes. J Lab Clin Med 1997; 129: 638-648.
42. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161-166.
43. Gass RJA, Gal J, Fogle PW, Detmar-Hanna D and Gerber JG. Neither dapsone hydroxylation nor cortisol 6 beta-hydroxylation detects the inhibition of CYP3A4 by HIV-I protease inhibitors. Eur 1 Clin Pharmacol 1998; 54: 741-747.
44. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS and Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999; 19: 293-296.
45. Tsunoda SM, Velez RL, von Moltke LL and Greenblatt DJ. Differentiation of intestinal and hepatic Cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Therapeut 1999; 66: 461-471.
46. Greenblatt OJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S and Shader RI. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Therapeut 1998; 64: 237-247.
47. Laurijssens BE and Greenblatt DI. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996; 30: 52-76.
48. Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol ALB, Mertzanis P, Duan SX, Wright CE and Shader RI. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Therapeut 1998; 64: 278-285.
49. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450lllA4. Molec Pharmacol 1989; 36: 89-96.
50. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirma- tion of a predicted interaction with ketoconazole. J Pharmacol Exper Therapeut 1996; 276: 370-379.
51. von Moltke LL, Greenblatt OJ, Duan SX, Harmatz JS and Shader RI. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro. Pharmacy Pharmacol Commu 1998; 4: 443-445.
52. von Moltke LL, Greenblatt OJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS and Shader RI. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111.
53. Barbhaiya RH, Shukla UA, Kroboth PD and Greene DS. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995; 15: 320-326.
54. Varhe A, Olkkola KT and Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Therapeu 1994; 56: 601-607.
55. Rickels K, Schweizer D, Case WG, DeMartinis N, Greenblatt DJ, Mandos LA and España FG. Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerablility. J Clin Psychopharmacol 1998; 18: 145-153.
56. Friedman H, Greenblatt DJ, Burstein ES, Harmatz JS and Shader RI. Population study of triazolam pharmacokinetics. Br J Clin Pharmacol 1986; 22: 639-642.